Avaleht › Ülekaalulisus › Arizona › Phoenix
Ülekaalulisus kliinilised uuringud linnas Phoenix, AZ
15 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid linnas Phoenix ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
VärbamineFaas 3
- Absolute Clinical Research, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
VärbamineFaas 3
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
VärbamineFaas 3
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
VärbamineFaas 3
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
VärbamineFaas 3
- Elite Clinical Studies, LLC, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
VärbamineFaas 3
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
VärbamineFaas 3
- AURORA-2 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
VärbamineFaas 2
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
VärbamineFaas 3Terved vabatahtlikud oodatud
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
VärbamineFaas 2
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
VärbamineFaas 4
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
VärbamineFaas 3
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
VärbamineVaatlusuuring
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
VärbamineFaas 3
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
VärbamineFaas 3
- The University of Arizona College of Medicine- Phoenix, Phoenix
Ülekaalulisus uuringud teistes linnades
- San Antonio, TX34 uuringut
- Houston, TX33 uuringut
- Chicago, IL28 uuringut
- Orlando, FL27 uuringut
- Las Vegas, NV23 uuringut
- Miami, FL23 uuringut
- Atlanta, GA20 uuringut
- Dallas, TX20 uuringut
- New York City, NY19 uuringut
- Jacksonville, FL19 uuringut
- Washington, DC19 uuringut
- Austin, TX18 uuringut
Muud uuringud linnas Phoenix
- Rinnavähk25 uuringut
- Käär- ja pärasoolevähk25 uuringut
- Rasvumine22 uuringut
- Mitteväikerakuline kopsuvähk20 uuringut
- Metastaatiline vähk20 uuringut
- Südamepuudulikkus18 uuringut
- Eesnäärmevähk17 uuringut
- Vähk (kõik liigid)17 uuringut
- Müeloom16 uuringut
- Pankreasevähk16 uuringut
- Kardiovaskulaarsed haigused16 uuringut
- Alzheimeri tõbi15 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.